On November 4, 2021 Clover Biopharmaceuticals, Ltd. (the "Company"; Stock code: 2197.HK) reported the allotment results of the global offering of the Company (the "Global Offering") (Press release, Clover Biopharmaceuticals, NOV 4, 2021, View Source [SID1234594660]). The Offer Price has been determined at HK$13.38 per Offer Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been over- subscribed. A total of 17,687 valid applications have been received pursuant to the Hong Kong Public Offering through the White Form eIPO service and through the CCASS EIPO service for a total of 66,001,500 Hong Kong Offer Shares, representing approximately 4.40 times of the total number of 15,000,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering.

As the number of Offer Shares validly applied for under the Hong Kong Public Offering represents less than 15 times of the number of Offer Shares initially available for subscription under the Hong Kong Public Offering, the reallocation procedures as described in the section headed "Structure of the Global Offering" in the Prospectus has not been effected.

The Offer Shares initially offered under the International Offering have been over-subscribed, representing approximately 3.21 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 135,000,000 Offer Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 22,500,000 Offer Shares in the International Offering and there are a total of 126 placees under the International Offering.

Based on the Offer Price of HK$13.38 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK$1870.2 million (assuming the Over-allotment Option is not exercised).

Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Friday, November 5, 2021 (Hong Kong time), dealings in the Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Friday, November 5, 2021 (Hong Kong time). The Shares will be traded in board lots of 500 Shares each. The stock code of the Shares is 2197.

Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited are the Joint Sponsors. Goldman Sachs (Asia) L.L.C., China International Capital Corporation Hong Kong Securities Limited and Credit Suisse (Hong Kong) Limited are the Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.

On November 4, 2021 bluebird bio, Inc. (NASDAQ: BLUE) reported the company has completed the tax-free spin-off of its oncology programs and portfolio into 2seventy bio, Inc., an independent, publicly-traded company (Press release, bluebird bio, NOV 4, 2021, View Source [SID1234594657]). bluebird bio will continue its work focused on severe genetic disease, with three near-term opportunities to bring transformative gene therapies to patients and their families in the U.S. 2seventy will begin regular-way trading on the NASDAQ under the stock ticker symbol "TSVT" on November 5, 2021. bluebird bio will continue to trade under the stock ticker symbol "BLUE."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Over more than a decade, bluebird bio has set the standard for gene therapy and with more than 485 patient years of experience, we have amassed the largest and deepest ex-vivo gene therapy data set in the world," said Andrew Obenshain, chief executive officer, bluebird bio. "As a dedicated severe genetic disease company, we are prepared to unlock the full value of our pipeline through the anticipated launch of three, first-in-class therapies for patients with sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy, and to realize the potential of gene therapy to transform lives for patents and their families now and in the future."

bluebird bio is led by an experienced team composed of tenured bluebird leaders and recent additions, focused on executing against a clear strategy to develop and commercialize the company’s lentiviral vector gene therapies and to deliver with increased fiscal discipline.

In September 2021, bluebird announced that it had submitted a biologics licensing application to the U.S. Food and Drug Administration for betibeglogene autotemcel (beti-cel) for patients with β-thalassemia who require regular red blood cell transfusions. The BLA filing for elivaldogene autotemcel (eli-cel, Lenti-D) for patients with cerebral adrenoleukodystrophy (CALD) is on track for the end of 2021.

bluebird bio will host a spotlight and regulatory update on its bb1111 (LentiGlobin for Sickle Cell Disease) product candidate, an investigational lentiviral vector gene therapy for sickle cell disease, for analysts and investors on Thursday, November 18, 2021, at 8:00 am ET. Investors may listen to the call by dialing (833) 857-1010 from locations in the United States or +1 (929) 517-0312 from outside the United States. Please refer to conference ID number 5780005.

On November 4, 2021 BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, reported the Company’s third quarter 2021 financial results will be released after market close on Thursday, November 11th (Press release, BioLife Science, NOV 4, 2021, View Source [SID1234594634]). The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day. Management will provide an overview of the Company’s financial results and a general business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at View Sourceearnings." target="_blank" title="View Sourceearnings." rel="nofollow">View Source Alternatively, you may access the live conference call by dialing 1 (844) 825-0512 or international callers at 1 (315) 625-6880 with the following Conference ID: 7075159. A webcast replay will be available approximately two hours after the call and will be archived on View Source for 90 days.

On November 4, 2021 Stand Up To Cancer (SU2C) reported the launch of a new public service announcement (PSA) campaign, in collaboration with Academy, Emmy and Grammy Award-winning artist, actor, activist and SU2C Ambassador Common, and with support from Bristol Myers Squibb (Press release, SU2C, NOV 4, 2021, https://www.prnewswire.com/news-releases/stand-up-to-cancer-with-support-from-bristol-myers-squibb-unveils-new-lung-cancer-psa-featuring-artist-actor-and-activist-common-814198693.html [SID1234594633]). The PSA raises awareness for lung cancer research and clinical trials. Lung cancer is the leading cause of cancer death among both men and women in the United States and represents nearly 25% of all cancer deaths.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the new broadcast PSA, Common highlights the profound impact lung cancer continues to have on the Black community. The hopeful, empowering and educational campaign addresses the importance of screening and treatment options, including cancer clinical trials. The campaign will come to life across print, digital, radio and out-of-home media, with the print and radio PSA being released in both English and Spanish-language.

"In 2014 my father died after his battle with cancer," said Common. "He was truly someone who inspired me and made me want to be better. I believe that we can do better for ourselves – especially as Black men when it comes to health. I’m honored to support Stand Up To Cancer’s campaign to bring awareness to lung cancer research."

This new campaign is the latest effort from Stand Up To Cancer that is being supported by Bristol Myers Squibb, who has provided funding for important SU2C research initiatives since 2014. Both organizations are committed to promoting and improving health equity in medically underserved communities. This awareness campaign was supported by a $5 million grant awarded to SU2C from Bristol Myers Squibb last year to help fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities. In 2020, Bristol Myers Squibb awarded Stand Up To Cancer a total of $10 million in grant funding to support lung cancer research.

"More than 235,000 new cases of lung cancer will be diagnosed this year in the United States and research shows there are stark disparities in lung cancer diagnoses among diverse and rural communities," said Sung Poblete PhD, RN, CEO of Stand Up To Cancer. "Stand Up To Cancer is committed to saving lives by accelerating cancer research and reducing barriers to clinical trial participation in medically underserved communities. We are thankful to Bristol Myers Squibb for their collaboration to support our efforts in lung cancer research and to Common for lending his voice and support to this important campaign."

Despite recent progress in treating lung cancer, the disease remains the leading cause of cancer death in the U.S. with particularly high death rates in rural communities and among Black men. Each year, over 25,000 Black men and women in the U.S. will be diagnosed with lung cancer. Black men are about 15% more likely to develop lung cancer than white men.

"Our mission at Bristol Myers Squibb is to transform lives through science, but that also means ensuring that all people affected by cancer can equally benefit from the latest science and treatments," said Wendy Short Bartie, senior vice president, US Oncology, Bristol Myers Squibb. "By bringing visibility to lung cancer inequities and encouraging diversity in clinical trials, this PSA will take an important step toward eliminating the dangerous disparities that exist for many underserved lung cancer patients. That’s why it was a clear fit for us to continue our longtime support of Stand Up To Cancer by aligning on this effort."

The broadcast and radio PSAs were developed by SU2C and production studio Society. The print campaign was produced by SU2C with photography by Matt Sayles.

This campaign is the latest in a series of PSAs by SU2C to increase awareness about the importance of cancer screenings and clinical trials in medically underserved communities. SU2C formally announced its Health Equity Initiative in January 2020. To date, the initiative has focused on increasing diversity in cancer clinical trials, initiating advocacy group collaborations and awareness campaigns, and funding research aimed at improving cancer outcomes and screening rates in medically underserved communities.

To learn more about this PSA visit, StandUpToCancer.org/LungCancer.

On November 4, 2021 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported that it has negotiated an amendment to its Licence Agreement for the Company’s focal adhesion kinase (FAK) asset AMP886 (Press release, Amplia Therapeutics, NOV 4, 2021, View Source;[email protected] [SID1234594632]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the initial Licence Agreement signed in March 2018 between the Company and Cancer Research UK (CRUK), the Company agreed to either file an Investigational New Drug application (IND) or initiate a Phase 1 clinical trial of AMP886 within 3 years. In March 2021, CRUK agreed to extend the term allowed for initiation of these activities, subject to further negotiations with the Company. CRUK has now agreed to extend the deadline for filing an IND or commencing a Phase 1 trial of AMP886 until 31 December 2023.

Amplia’s CEO Dr John Lambert commented that "We are extremely pleased that we have been able to obtain this extension from CRUK and are grateful for their support and collaboration on this matter. The additional time that has been made available will allow us to undertake further preclinical studies with this promising molecule which has a unique activity profile, and identify therapeutic indications for which it is best suited before we initiate formal development. Meanwhile, our efforts to push AMP945 onward into Phase 2 trials are proceeding in earnest."

This ASX announcement has been approved and authorised for release by the CEO of Amplia Therapeutics.